文献速递头颈外科

头颈癌患者拒绝治疗的影响因素与生存结局

Factors predicting for patient refusal of head and neck cancer therapy.
PubMed 文献 · Head Neck · 2019-10-04

拒绝治疗的预测因素包括高龄、女性、非裔美国人/其他种族、非私人保险、更多合并症、更晚期疾病和居住地离治疗机构更近(P<.05)。拒绝治疗者生存更差(中位79.1 vs 8.7个月,P<.001)。

要点

  • 高龄、女性、非私人保险、更多合并症和更晚期疾病者更易拒绝治疗。
  • 拒绝治疗者中位生存仅8.7个月,显著差于接受治疗者的79.1个月。

核心结论

  • 头颈癌拒绝肿瘤治疗相对罕见,且影响因素呈多因素性。
  • 拒绝根治性治疗与显著更差的生存相关(中位79.1 vs 8.7个月,P<.001)。

研究设计与样本

  • 基于美国国家癌症数据库(National Cancer Database)的回顾性查询。
  • 纳入非转移性头颈鳞状细胞癌患者,肿瘤治疗指接受手术、放疗或化疗。

主要发现

  • 拒绝治疗的预测因素包括高龄、女性、非裔美国人/其他种族、非私人保险、更多合并症、更晚期疾病和居住地离治疗机构更近(P<.05)。
  • 有癌症病史、西班牙裔、在学术中心治疗及来自高收入县的患者更少拒绝治疗(P<.05)。
  • 拒绝根治性治疗者生存更差(中位79.1 vs 8.7个月,P<.001)。

临床怎么用

  • 临床中应关注高龄、女性、非私人保险、合并症多及晚期患者,识别拒绝治疗高风险人群。
  • 对拒绝治疗者需充分沟通生存预后差异,并针对性干预以减少拒绝。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to evaluate the national rate of treatment refusal in head and neck cancer (HNC). METHODS: The National Cancer Database was queried for nonmetastatic squamous cell carcinoma of the head and neck. Oncologic therapy referred to receipt of surgery, radiotherapy, or chemotherapy. RESULTS: Compared to the 230 424 patients who received treatment, 2965 (1.3%) were reported to have refused definitive therapy. Predictors included older age, female sex, African-American/other race, nonprivate insurance, greater comorbidities, more advanced disease, and residence closer to the treating facility (P < .05). Patients with a prior history of cancer, Hispanic race, those treated at academic centers, and those from higher income counties were less likely to refuse therapy (P < .05). Patients who refused definitive therapy experienced poorer survival (median 79.1 vs 8.7 months, P < .001). CONCLUSIONS: Refusing oncologic therapy is relatively rare in HNC and appears to be multifocal in nature.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Amini A, Verma V, Li R, et al. Factors predicting for patient refusal of head and neck cancer therapy. Head Neck. 2019. PMID: 31584746. doi:10.1002/hed.25966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。